Ticker

Clene NASDAQ: CLNN is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an interview.

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 and 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term…

SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 19, 2026 Time of Presentation: 3:10 p.m.

Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.78 per share a year ago.

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-treated patients whose NfL declined or stabilized SALT LAKE CITY, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced its second quarter 2026 financial results and provided recent updates on its…